- Keywords > Clinical Practice Guidelines (CPGs)
- Keywords > criteria of medicines selection
- Keywords > HIV infection and STIs
- Keywords > opportunistic infections and other HIV-related
- Keywords > reproductive tract infections
- Keywords > sexual and reproductive health
- Keywords > sexually transmitted infections (STIs)
- Keywords > treatment guidelines
- Keywords > treatment protocols
(2004; 88 pages)
Bacterial vaginosis in pregnancy
There is evidence that bacterial vaginosis is associated with an increased incidence of adverse pregnancy outcomes (e.g., premature rupture of membranes, pre-term delivery and low birth weight). Symptomatic pregnant women should be treated, and those with a history of previous pre-term delivery should be screened to detect asymptomatic infections. Pregnant women with recurrence of symptoms should be re-treated. Screening of asymptomatic pregnant women without a history of prior pre-term delivery is not recommended.
Metronidazole is not recommended for use in the first trimester of pregnancy, but it may be used during the second and third trimesters. Lower doses of metronidazole are recommended throughout pregnancy, to reduce the risks of any adverse effects.
• metronidazole, 200 or 250mg orally three times daily for 7 days.
• metronidazole, 2g orally, as a single dose
• clindamycin, 300 mg orally twice daily for 7 days
• metronidazole gel, 0.75%, 5g twice daily intravaginally for 7 days.